MD20140108A2 - Anticorpi împotriva metaloproteinazei 9 matriciale - Google Patents

Anticorpi împotriva metaloproteinazei 9 matriciale Download PDF

Info

Publication number
MD20140108A2
MD20140108A2 MDA20140108A MD20140108A MD20140108A2 MD 20140108 A2 MD20140108 A2 MD 20140108A2 MD A20140108 A MDA20140108 A MD A20140108A MD 20140108 A MD20140108 A MD 20140108A MD 20140108 A2 MD20140108 A2 MD 20140108A2
Authority
MD
Moldova
Prior art keywords
antibodies
matrix metalloproteinase
mmp9
functional fragment
binding proteins
Prior art date
Application number
MDA20140108A
Other languages
English (en)
Russian (ru)
Inventor
Джоан И. Адамкевич
Виктория СМИТ
Цзун ТАЙ
Майкл Дж. ХОКИНС
Original Assignee
Gilead Biologics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2012/027160 external-priority patent/WO2013130078A1/en
Application filed by Gilead Biologics, Inc. filed Critical Gilead Biologics, Inc.
Publication of MD20140108A2 publication Critical patent/MD20140108A2/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Invenţia se referă la imunologie, în special la compoziţii şi metode de utilizare a lor, care implică proteine de legare, de exemplu anticorpi şi fragmente de legare a antigenului acestora, care se leagă de metaloproteinaza matricială-9 (MMP9) (MMP9 este cunoscută şi ca gelatinaza-B), cum ar fi în cazul în care proteinele de legare cuprind un lanţ imunoglobulinic greu (Ig) (fragmentul funcţional al acestuia) şi un lanţ uşor Ig (fragmentul funcţional al acestuia).
MDA20140108A 2012-02-29 2013-02-28 Anticorpi împotriva metaloproteinazei 9 matriciale MD20140108A2 (ro)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261605181P 2012-02-29 2012-02-29
PCT/US2012/027160 WO2013130078A1 (en) 2012-02-29 2012-02-29 Antibodies to matrix metalloproteinase 9
US201361755444P 2013-01-22 2013-01-22
PCT/US2013/028456 WO2013130905A1 (en) 2012-02-29 2013-02-28 Antibodies to matrix metalloproteinase 9

Publications (1)

Publication Number Publication Date
MD20140108A2 true MD20140108A2 (ro) 2015-03-31

Family

ID=49003113

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20140108A MD20140108A2 (ro) 2012-02-29 2013-02-28 Anticorpi împotriva metaloproteinazei 9 matriciale

Country Status (23)

Country Link
US (2) US9732156B2 (ro)
EP (2) EP3255063A3 (ro)
JP (3) JP6144286B2 (ro)
KR (1) KR20140130513A (ro)
CN (2) CN107184974A (ro)
AP (1) AP2014007921A0 (ro)
AU (1) AU2013203619B2 (ro)
BR (1) BR112014021081A2 (ro)
CA (1) CA2865501A1 (ro)
CL (1) CL2014002258A1 (ro)
CO (1) CO7061039A2 (ro)
CR (1) CR20140451A (ro)
EA (1) EA201491599A1 (ro)
EC (1) ECSP14020644A (ro)
HK (4) HK1204926A1 (ro)
MD (1) MD20140108A2 (ro)
MX (2) MX2014010447A (ro)
MY (1) MY167236A (ro)
NZ (1) NZ629178A (ro)
PH (1) PH12014501927A1 (ro)
SG (2) SG10201610788VA (ro)
WO (1) WO2013130905A1 (ro)
ZA (1) ZA201406318B (ro)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101827048B1 (ko) 2010-08-27 2018-02-07 길리아드 바이오로직스, 인크. 매트릭스 메탈로프로테이나제 ９에 대한 항체
CN103649336A (zh) 2011-05-10 2014-03-19 雀巢产品技术援助有限公司 用于个体化治疗管理的疾病活动性表征方法
US9550836B2 (en) 2012-02-29 2017-01-24 Gilead Biologics, Inc. Method of detecting human matrix metalloproteinase 9 using antibodies
NZ629178A (en) 2012-02-29 2016-09-30 Gilead Biologics Inc Antibodies to matrix metalloproteinase 9
KR102332302B1 (ko) * 2013-09-13 2021-12-01 제넨테크, 인크. 세포주에서 숙주 세포 단백질 및 재조합 폴리펩티드 생성물을 검출 및 정량화하기 위한 조성물 및 방법
SG10201802525QA (en) 2013-09-13 2018-04-27 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
EP3099324B1 (en) 2014-01-30 2020-04-01 Coherus Biosciences, Inc. Perfusion media
EP3110847A1 (en) * 2014-02-27 2017-01-04 Gilead Sciences, Inc. Antibodies to matrix metalloproteinase 9 and methods of use thereof
EP2985296A1 (en) * 2014-08-13 2016-02-17 Calypso Biotech SA Antibodies specific for MMP9
MY198017A (en) 2014-08-19 2023-07-26 Merck Sharp & Dohme Anti-tigit antibodies
WO2017030823A2 (en) * 2015-08-14 2017-02-23 Merck Sharp & Dohme Corp. Anti-tigit antibodies
TW201726130A (zh) * 2015-10-02 2017-08-01 基利科學股份有限公司 用於治療癌症之組合療法
US20170174788A1 (en) * 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and an mmp9 binding protein for treating inflammatory disorders
KR101783907B1 (ko) * 2016-03-15 2017-10-10 다이노나(주) ＣＤ66ｃ에 대한 항체와 화학치료제를 포함하는 폐암 예방 또는 치료용 약학조성물
CA3019003A1 (en) * 2016-04-08 2017-10-12 Gilead Sciences, Inc. Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
TWI676482B (zh) * 2017-03-23 2019-11-11 高雄醫學大學 盤基蛋白結構域受體１的抑制劑及活化劑及其用途
KR20200009095A (ko) 2017-05-31 2020-01-29 프로메테우스 바이오사이언시즈, 인크. 크론병 환자에서 점막 치유를 평가하는 방법
JP7109440B2 (ja) 2017-07-18 2022-07-29 第一三共株式会社 活性型ｍｍｐ－９結合ペプチド
WO2019094608A1 (en) 2017-11-08 2019-05-16 Denali Therapeutics Inc. Anti-bace1 antibodies and methods of use thereof
US12116415B2 (en) * 2018-10-09 2024-10-15 Single Cell Technology, Inc. Anti-BCMA antibodies
WO2020118293A2 (en) * 2018-12-07 2020-06-11 Georgia Tech Research Corporation Antibodies that bind to natively folded myocilin
IL264768A (en) 2019-02-10 2020-08-31 Sagi Irit Anti-matrix metalloproteinase 7 (mmp-7) inhibitory antibody and uses thereof
WO2020237092A2 (en) * 2019-05-21 2020-11-26 The Regents Of The University Of California Mmp-9 antibodies and methods of use thereof
US11332546B2 (en) 2019-05-21 2022-05-17 The Regents Of The University Of California Protease inhibitory antibodies and methods of use thereof
CA3160181A1 (en) 2019-12-17 2021-06-24 The Board Of Regents Of The University Of Texas System Novel ddr1 antibodies and uses thereof
WO2021202592A2 (en) * 2020-03-30 2021-10-07 Oregon Health & Science University Monoclonal antibodies for intracellular delivery of payloads
EP4475852A2 (en) * 2022-02-09 2024-12-18 Sera Prognostics, Inc. Shbg and ibp4 antibodies and methods using same
CN114292834B (zh) * 2022-03-09 2022-05-31 天津辅元生物医药科技有限公司 一种融合蛋白酶及其制备方法、其在提取i型胶原蛋白中的应用以及该i型胶原蛋白的用途
WO2025076396A1 (en) * 2023-10-04 2025-04-10 The Trustees Of The University Of Pennsylvania Methods of treating, ameliorating and/or preventing fibrodysplasia ossificans progressiva and heterotopic ossification, and kits for the same
CN117986368B (zh) * 2023-10-18 2024-11-29 深圳大学 抗肿瘤抗炎症相关的纳米抗体及其制备方法与应用
CN119060188B (zh) * 2024-08-30 2025-09-12 武汉爱博泰克生物科技有限公司 抗人基质金属蛋白酶9抗体、抗体对和检测试剂盒
CN119193495A (zh) * 2024-09-25 2024-12-27 广州通识生物医药有限公司 一种基因修饰的间充质干细胞的制备方法及其应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
DE69412466T2 (de) 1993-11-30 1999-04-29 Fuji Yakuhin Kogyo K.K., Takaoka, Toyama Neue metalloprotease und kodierende dna dafür
US5612030A (en) 1995-01-17 1997-03-18 University Of Kentucky Research Foundation Anti-idiotype monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
AU770718B2 (en) 1998-06-05 2004-02-26 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to CD38 to treat multiple myeloma
CA2379373A1 (en) 1999-07-13 2001-01-18 University Of Southern California Novel method and composition for inhibition of angiogenesis using antagonists based on mmp-9 and .beta.1 integrins
US7101975B1 (en) 1999-07-13 2006-09-05 University Of Southern California Method and composition for inhibition of angiogenesis using antagonists based on MMP-9 and β1 integrins
WO2002066057A2 (en) 2001-02-23 2002-08-29 Biophage Inc. Methods and compositions for preventing and treating neutrophil-mediated diseases
SE0102298D0 (sv) 2001-06-27 2001-06-27 Astrazeneca Ab Crystal structure of enzyme and uses thereof
WO2003006006A1 (en) 2001-07-09 2003-01-23 The Regents Of The University Of California Use of matrix metalloproteinase inhibitors to mitigate nerve damage
AU2002352089A1 (en) 2001-11-23 2003-06-10 Universite Catholique De Louvain Medical use of antibodies directed against human matrix metalloproteinases or related tissue proteinases for the treatment of abnormal uterine bleeding and endometriosis
AU2003270330B2 (en) 2002-09-06 2009-07-30 Alexion Pharmaceuticals, Inc. Method of treatment of asthma using antibodies to complement component C5
WO2004076614A2 (de) 2003-02-27 2004-09-10 Bernd Hinzmann Humane nukleinsäuresequenzen aus prostatakarzinomen
EP1610678B1 (en) * 2003-04-04 2011-07-27 Yeda Research And Development Co., Ltd. Antibodies for inhibiting the activity of mmp-2 and mmp-9
CA2550551C (en) * 2004-01-16 2013-10-29 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
WO2006037513A1 (en) 2004-10-09 2006-04-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with matrix metalloproteinase 9 (mmp9)
EP1904846A4 (en) 2005-06-29 2009-03-18 Rules Based Medicine Inc METHOD AND KITS FOR THE DIAGNOSIS OF ACUTE CORONARY SYNDROME
CN101370832B (zh) * 2005-12-02 2014-07-02 健泰科生物技术公司 结合多肽及其用途
EP1957540B1 (en) 2005-12-02 2012-06-13 Genentech, Inc. Binding polypeptides and uses thereof
WO2007144781A2 (en) 2006-04-21 2007-12-21 Diagnotech Pty. Ltd. Diagnostic methods and kits utilizing antibodies for metalloproteases
WO2008088864A2 (en) 2007-01-18 2008-07-24 The Trustess Of Columbia University In The City Of New York Matrix metalloproteinase-9-related methods
EP2155691B1 (en) 2007-02-23 2016-01-13 Yeda Research and Development Co. Ltd. Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins
PE20090765A1 (es) 2007-06-08 2009-07-10 Irm Llc Metodos y composiciones para inducir la apoptosis en celulas cancerosas
ES2402334T3 (es) 2007-08-02 2013-04-30 Gilead Biologics, Inc Procedimientos y composiciones para el tratamiento y el diagnóstico de la fibrosis
KR20100071972A (ko) 2007-08-15 2010-06-29 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 Ｍｍｐ-9의 조절인자 및 그의 용도
US8147836B2 (en) 2007-12-17 2012-04-03 Dyax Corp. Compositions and methods for treating osteolytic disorders comprising MMP-14 binding proteins
WO2009111450A2 (en) 2008-03-03 2009-09-11 Dyax Corp. Metalloproteinase 9 binding proteins
JP2011517320A (ja) 2008-03-03 2011-06-02 ダイアックス コーポレーション メタロプロテアーゼ９結合タンパク質およびメタロプロテアーゼ２結合タンパク質
US20100098659A1 (en) * 2008-10-22 2010-04-22 Revalesio Corporation Compositions and methods for treating matrix metalloproteinase 9 (mmp9)-mediated conditions
US20110262396A1 (en) 2008-10-22 2011-10-27 Dyax Corp. Combination treatments comprising protease binding proteins for inflammatory disorders
WO2010059543A1 (en) * 2008-11-20 2010-05-27 Merck Sharp & Dohme Corp. Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use
DE102009030321A1 (de) * 2009-06-24 2011-01-05 Siemens Aktiengesellschaft Verfahren zur Abbildung von Tumorgewebe
EA201270701A1 (ru) 2010-01-27 2013-01-30 Йеда Рисеч Энд Девелопмент Ко. Лтд. Ингибирующие металлопротеины антитела
BR112012019693A2 (pt) 2010-02-04 2017-06-20 Gilead Biologics Inc anticorpos que se ligam à lisil oxidase-like 2 (loxl2) e métodos de uso para eles.
US8896483B2 (en) * 2010-07-15 2014-11-25 Evgeny Markin Method of automatic target angle tracking by monopulse radar under conditions of interference distorting location characteristic
KR101827048B1 (ko) * 2010-08-27 2018-02-07 길리아드 바이오로직스, 인크. 매트릭스 메탈로프로테이나제 ９에 대한 항체
US8003110B1 (en) * 2011-01-24 2011-08-23 Matthias W. Rath Metalloproteinase oligopeptides and their therapeutic use
US9550836B2 (en) * 2012-02-29 2017-01-24 Gilead Biologics, Inc. Method of detecting human matrix metalloproteinase 9 using antibodies
NZ629178A (en) 2012-02-29 2016-09-30 Gilead Biologics Inc Antibodies to matrix metalloproteinase 9

Also Published As

Publication number Publication date
CL2014002258A1 (es) 2015-02-20
ECSP14020644A (es) 2015-09-30
US20180002446A1 (en) 2018-01-04
ZA201406318B (en) 2016-07-27
HK1204981A1 (en) 2015-12-11
SG10201610788VA (en) 2017-03-30
JP2018150343A (ja) 2018-09-27
HK1204926A1 (en) 2015-12-11
HK1248246A1 (en) 2018-10-12
AU2013203619A1 (en) 2013-09-19
CN104271156B (zh) 2017-06-16
PH12014501927A1 (en) 2014-11-24
EA201491599A1 (ru) 2015-05-29
HK1244671A1 (zh) 2018-08-17
NZ629178A (en) 2016-09-30
US9732156B2 (en) 2017-08-15
EP2819697A4 (en) 2016-03-09
MY167236A (en) 2018-08-14
AP2014007921A0 (en) 2014-09-30
CO7061039A2 (es) 2014-09-19
CN104271156A (zh) 2015-01-07
EP3255063A2 (en) 2017-12-13
JP2015509959A (ja) 2015-04-02
KR20140130513A (ko) 2014-11-10
SG11201405273YA (en) 2014-09-26
US20130224210A1 (en) 2013-08-29
CN107184974A (zh) 2017-09-22
BR112014021081A2 (pt) 2017-07-04
EP3255063A3 (en) 2018-02-07
JP6343368B2 (ja) 2018-06-13
JP2017178952A (ja) 2017-10-05
MX2014010447A (es) 2015-06-23
JP6144286B2 (ja) 2017-06-07
MX2018007630A (es) 2023-04-12
AU2013203619B2 (en) 2015-02-26
WO2013130905A1 (en) 2013-09-06
EP2819697A1 (en) 2015-01-07
CA2865501A1 (en) 2013-09-06
CR20140451A (es) 2014-11-17

Similar Documents

Publication Publication Date Title
MD20140108A2 (ro) Anticorpi împotriva metaloproteinazei 9 matriciale
MD20140107A2 (ro) Anticorpi împotriva metaloproteinazei 9 din matrice
PH12016501691A1 (en) Antibodies to matrix metalloproteinase 9
EA201591153A1 (ru) Антитела, связывающиеся с tl1a, и их применение
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
MX382398B (es) Proteinas de union a antigeno st2.
MX2011011754A (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b.
EA201491214A1 (ru) Композиции и способы применения антител, нацеленных на фактор p
JOP20160131B1 (ar) الأجسام المضادة للعامل xi وطرق الاستخدام
EA201591091A1 (ru) Антигенсвязывающие белки для bcma
AR105267A1 (es) Anticuerpos de unión a tau
MX2015005719A (es) Terapias de combinacion que usan moleculas de union anti-psl y pcrv de pseudomonas.
EA201291065A1 (ru) Антитела против vla-4
EA201590918A1 (ru) Антитела к bmp-6
EA201990895A1 (ru) Антитела к о1 и варианты их применения
MX2016011177A (es) Anticuerpos a la metaloproteinasa de matriz 9 y metodos de uso de los mismos.
TH148296A (th) แอนติบอดีต้านเมทริกซ์เมทัลโลโปรตีเนส 9 (Antibodies to matrix metalloproteinase 9)
CL2010000521A1 (es) Anticuerpo aislado o fragmento que bloquea la fijacion de la union de la proteina wise; secuencias de cdr de la cadena liviana y pesada; polipeptido inmunogenico de wise; composicion farmaceutica que comprende dicho anticuerpo.

Legal Events

Date Code Title Description
FA9A Abandonment or withdrawal of application (patent for invention)